Product Description:
Paclitaxel is a monomeric diterpenoid compound extracted from the bark of the natural plant Taxus. It is a complex secondary metabolite and the only known drug that can promote microtubule polymerization and stabilize polymerized microtubules. Isotope tracing indicates that paclitaxel only binds to polymerized microtubules and does not react with unpolymerized microtubule protein dimers. After contact with paclitaxel, cells accumulate a large number of microtubules inside the cell, which interfere with various functions of the cell, especially stopping cell division at the mitotic stage and blocking normal cell division. Through II- III clinical studies, paclitaxel is mainly applicable to ovarian cancer and breast cancer, and also has certain effects on lung cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma, and brain tumor.
So far, there are only two types of paclitaxel raw materials on the international market: one comes from various types of yew bark; Another method is to extract "10 berry gibberellin" from European ornamental yew branches, and then semi synthesize it into docetaxel (docetaxel), which has a structure very similar to naturally extracted paclitaxel. Both of these active pharmaceutical ingredients are popular in the international pharmaceutical market and have long been in short supply. According to relevant departments' estimates, the sales ratio of paclitaxel active pharmaceutical ingredient to docetaxel active pharmaceutical ingredient is approximately 10:1.
In the United States, paclitaxel injections (trade name: Paclitaxel) are mainly exclusively produced by Bristol Myers Squibb. Currently, there are about two or three pharmaceutical companies producing paclitaxel raw materials and formulations, but the market is basically monopolized by Bristol Myers Squibb. The total sales of paclitaxel formulations produced by other companies are only a fraction of that of Bristol Myers Squibb. The raw materials and preparations of docetaxel are mainly produced by the French company Plank, as well as several companies in the UK, Italy, and other countries, with Plank having the largest production capacity.
Paclitaxel is the preferred anti-tumor drug in hospitals worldwide. In recent years, the incidence rate of tumors in the world has nearly doubled compared with 10 years ago. Malignant tumors such as lung cancer, breast cancer and ovarian cancer are also prone to occur. These cancer patients are the main users of paclitaxel. Overall, sales of paclitaxel will only increase and not decrease until a new plant-based anti-cancer drug can replace its position.
According to the latest figures released by the World Health Organization, the United States has become the world's top cancer prone country, with an annual increase of 1.4 million new cancer cases, accounting for approximately 14% of global cancer patients that year. The United States remains the largest consumer of paclitaxel to this day. With the increase of the incidence rate of cancer in the United States, it is believed that the sales of paclitaxel, as the main drug against advanced malignant tumors, will continue to rise rapidly. The United States and other developed countries have already developed a set of optimal compatibility schemes for paclitaxel and other anti-cancer drugs in clinical use over the past decade. Their medical departments cannot do without paclitaxel, which is the "backbone". Therefore, the demand for paclitaxel raw materials will also rise rapidly.
Product Function:
It has good effect in the treatment of refractory ovarian cancer and breast cancer with drug resistance such as ovarian cancer and platinum, and has good prospects in the treatment of prostate cancer, head and neck cancer, esophageal cancer, germ cell tumor, endometrial cancer, lymphoma, bladder cancer cancer, upper gastrointestinal cancer, small cell and non small cell lung cancer.
Application:
1. Antitumor drugs. It is used to treat metastatic breast cancer and metastatic ovarian cancer. A broad-spectrum anti-tumor plant drug used to treat ovarian cancer, breast cancer and other diseases
2. Effective anti-tumor drugs; Combining with the N-terminal region of β - tubulin promotes highly stable microtubule forming bodies, resists depolymerization, prevents normal cell division, and captures in the G2/M phase of the cell cycle.
3. A microtubule inhibitor that promotes microtubule protein polymerization, inhibits depolymerization, maintains microtubule protein stability, and suppresses cell mitosis. Acting on human endothelial cells, IC50 is 0.1 pM.
FAQ:
What's the MOQ?
Generally the MOQ is 1kg, Best 25KG/DRUM
Is there any discount?
Yes, we will give you the best discount according to the size of your order!
How can I confirm the product quality before placing orders?
We will send you the existing sample or prepare the sample according to your request and send it to you for your confirmation!
How do you treat quality complaint?
If the quality problem is confirmed to be caused by us, we will replace the goods or refund your payment immediately!
How to contact with us ?
Through SKYPE, WHATSAPP, WeChat, and E-mail.
How to place an order & payment ?
(1). Conduct product consultation, (2). Determine the sample, (3).After the sample quality meets the requirements, send us the PO, (4). We reply to PI (5). The customer completes the payment, (6). Receive payment for goods, export products, (7). The customer receives the goods and completes the order.
Cooperative customers: Our products are exported to European and American countries. It also has a large customer base in Southeast Asia and other regions.
After-sale service: If the quality problem is confirmed to be caused by us, we will replace the goods or refund your payment immediately!
100% responsible person, safe and reliable, integrity first.
Audited Supplier 
){kind=link}